Relmada Therapeutics Stock Revenue
| RLMD Stock | USD 0.37 0.05 11.90% |
Relmada Therapeutics fundamentals help investors to digest information that contributes to Relmada Therapeutics' financial success or failures. It also enables traders to predict the movement of Relmada Stock. The fundamental analysis module provides a way to measure Relmada Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relmada Therapeutics stock.
| Last Reported | Projected for Next Year |
Relmada | Revenue |
Relmada Therapeutics Company Revenue Analysis
Relmada Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Relmada
Projected quarterly revenue analysis of Relmada Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Relmada Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Relmada Therapeutics' stock price.
Relmada Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Relmada Therapeutics is extremely important. It helps to project a fair market value of Relmada Stock properly, considering its historical fundamentals such as Revenue. Since Relmada Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Relmada Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Relmada Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Relmada Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Relmada Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Relmada Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relmada Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics of similar companies.Relmada Therapeutics is currently under evaluation in revenue category among its peers.
Relmada Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Relmada Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Relmada Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Relmada Therapeutics' value.| Shares | Two Sigma Advisers, Llc | 2024-09-30 | 242.5 K | Deutsche Bank Ag | 2024-09-30 | 224.8 K | Bank Of America Corp | 2024-09-30 | 206.7 K | Two Sigma Investments Llc | 2024-09-30 | 191.3 K | Bridgeway Capital Management, Llc | 2024-09-30 | 181.1 K | Shay Capital Llc | 2024-09-30 | 175.5 K | Rbf Llc | 2024-09-30 | 165.5 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 157.7 K | Barclays Plc | 2024-09-30 | 146 K | Franklin Resources Inc | 2024-09-30 | 1.3 M | Vanguard Group Inc | 2024-09-30 | 1.3 M |
Relmada Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | (41.52 M) | ||||
| Shares Outstanding | 30.17 M | ||||
| Shares Owned By Insiders | 8.04 % | ||||
| Shares Owned By Institutions | 46.06 % | ||||
| Number Of Shares Shorted | 1.06 M | ||||
| Price To Earning | (1.27) X | ||||
| Price To Book | 0.23 X | ||||
| EBITDA | 4.91 M | ||||
| Net Income | (98.79 M) | ||||
| Cash And Equivalents | 211.96 M | ||||
| Cash Per Share | 7.05 X | ||||
| Total Debt | 12.19 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 2.84 X | ||||
| Cash Flow From Operations | (51.66 M) | ||||
| Short Ratio | 4.52 X | ||||
| Earnings Per Share | (2.86) X | ||||
| Target Price | 0.87 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 12.6 M | ||||
| Total Asset | 97.55 M | ||||
| Retained Earnings | (560.9 M) | ||||
| Working Capital | 85.31 M | ||||
| Current Asset | 9.3 M | ||||
| Current Liabilities | 3.06 M | ||||
| Net Asset | 97.55 M |
About Relmada Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relmada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Relmada Therapeutics Piotroski F Score and Relmada Therapeutics Altman Z Score analysis. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.